<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Hematol Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Hematol Oncol</journal-id>
      <journal-title-group>
        <journal-title>Journal of Hematology &amp; Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-8722</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25652695</article-id>
      <article-id pub-id-type="pmc">4332927</article-id>
      <article-id pub-id-type="publisher-id">100</article-id>
      <article-id pub-id-type="doi">10.1186/s13045-014-0100-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Arahata</surname>
            <given-names>Masahisa</given-names>
          </name>
          <address>
            <email>rqxhf297@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shimizu</surname>
            <given-names>Yukihiro</given-names>
          </name>
          <address>
            <email>rsf14240@nifty.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Asakura</surname>
            <given-names>Hidesaku</given-names>
          </name>
          <address>
            <email>hasakura@staff.kanazawa-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakao</surname>
            <given-names>Shinji</given-names>
          </name>
          <address>
            <email>snakao8205@staff.kanazawa-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Internal Medicine, Nanto Municipal Hospital, 938 Inami, Nanto, Toyama 932-0211 Japan </aff>
        <aff id="Aff2"><label/>Department of Internal Medicine (III), Kanazawa University Graduate School of Medical Science, Kanazawa, Japan </aff>
        <aff id="Aff3"><label/>Department of Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>6</day>
        <month>2</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>6</day>
        <month>2</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>5</elocation-id>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>12</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Arahata et al.; licensee Biomed Central. 2015</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>The prognosis of relapsed acute myeloid leukemia (AML) in elderly patients is dismal, even if the AML exhibits a good prognostic karyotype, such as inv(16)(p13.1q22). We present a 72-year-old female with AML with inv(16)(p13.1q22) who suffered five episodes of relapse with temporary complete remission. Maintenance chemotherapy with oral cytarabine ocfosfate hydrate eventually produced persistent molecular complete remission of her AML that had not been induced by conventional regimens including intensive chemotherapy and low dose cytarabine therapy. The high level of tolerability to oral cytarabine ocfosfate hydrate may offer elderly patients with this type of AML a good chance for a cure.</p>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1186/s13045-014-0100-6) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Cytarabine ocfosfate hydrate</kwd>
        <kwd>Acute myeloid leukemia</kwd>
        <kwd>Inv(16)(p13.1q22)</kwd>
        <kwd>Refractory</kwd>
        <kwd>Elderly</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Acute myeloid leukemia (AML) with inv(16)(p13.1q22) is characterized by a favorable prognosis and good response to treatment with cytarabine [<xref ref-type="bibr" rid="CR1">1</xref>]. The strategy of treatment for AML with inv(16)(p13.1q22) is based on a series of intensive chemotherapy, which is considered more curable than prolonged maintenance chemotherapy with low-dose anti-leukemic agents even in the elderly [<xref ref-type="bibr" rid="CR2">2</xref>-<xref ref-type="bibr" rid="CR4">4</xref>]. On the other hand, low-dose cytarabine therapy (LDAC) is recommended for elderly patients with AML who are not considered suitable for intensive chemotherapy [<xref ref-type="bibr" rid="CR5">5</xref>-<xref ref-type="bibr" rid="CR8">8</xref>], but LDAC can rarely induce persistent remission [<xref ref-type="bibr" rid="CR9">9</xref>]. Once they relapse, their prognosis is usually dismal, even if the AML is associated with inv(16)(p13.1q22) [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref>].</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>In December 2006, a 72-year-old female was admitted to our hospital presenting with general malaise and dyspnea. A physical examination revealed anemic palpebral conjunctiva and purpura of the extremities. The complete blood count indicated severe anemia and thrombocytopenia as well as mild leukocytosis with 22.5% blast cells (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). A bone marrow examination showed a total nucleated cell count of 41,000/&#x3BC;L with 67.0% blasts (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1A). A cytogenetic analysis of the bone marrow cells with G-banding showed 46,XX,inv(16)(p13.1q22) in all 20 dividing cells (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1B). Based on these findings, the patient was diagnosed as having AML with inv(16)(p13.1q22).</p>
      <p>The patient achieved complete remission (CR) after one course of induction chemotherapy comprising behenoyl cytarabine and daunorubicin according to a study protocol [<xref ref-type="bibr" rid="CR12">12</xref>] (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). However, the AML relapsed four months after the completion of the last cycle of consolidation therapy. Re-induction chemotherapy using the same regimen as the first induction induced a second CR. Thereafter, the patient suffered four further episodes of relapse with temporary remission (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The failure to achieve durable remission even with high-dose consolidation therapy and its toxicities prompted us to select palliative care with LDAC at the third relapse. After achieving the sixth CR, the patient declined further treatment with LDAC due to toxicity. Therefore, oral cytarabine ocfosfate hydrate (SPAC) was started in order to maintain remission in November 2011. The SPAC therapy was not associated with any significant toxicity. The <italic>CBFB-MYH11</italic> fusion mRNA in the peripheral blood became negative after twelve courses of SPAC therapy, which was terminated in October 2013. The patient has since remained in molecular remission without chemotherapy (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Chemotherapy regimens and adverse events in the present case</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th valign="middle" rowspan="2"/><th valign="middle" rowspan="2">
<bold>Chemotherapy</bold>
</th><th valign="middle" rowspan="2">
<bold>No.</bold>
</th><th valign="middle" rowspan="2">
<bold>Regimen</bold>
</th><th valign="middle" rowspan="2">
<bold>PS</bold>
</th><th valign="middle" rowspan="2">
<bold>BI</bold>
</th><th valign="middle" colspan="6">
<bold>Grade of adverse event*</bold>
</th><th valign="middle" rowspan="2">
<bold>BW</bold>
<break/>
<bold>(kg)</bold>
</th><th valign="middle" rowspan="2">
<bold>Complications</bold>
</th></tr><tr valign="top"><th valign="middle">
<bold>Neutropenia</bold>
</th><th valign="middle">
<bold>FN or infecton</bold>
</th><th valign="middle">
<bold>Anemia</bold>
</th><th valign="middle">
<bold>Thrombocytopenia</bold>
</th><th valign="middle">
<bold>Anorexia</bold>
</th><th valign="middle">
<bold>Weight loss</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="9">Onset to 1st CR</td><td rowspan="2">Induction</td><td align="center" rowspan="2">1</td><td>BHAC 200 mg/m<sup>2</sup> IV day 1-8</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">100</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">44.4</td><td rowspan="2"/></tr><tr valign="top"><td>DNR 40 mg/m<sup>2</sup> IV day 1-3</td></tr><tr valign="top"><td rowspan="2">Consolidation</td><td align="center" rowspan="2">2</td><td>BHAC 200 mg/m<sup>2</sup> IV day 1-5</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">100</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">41.6</td><td rowspan="2">Sepsis</td></tr><tr valign="top"><td>MIT 7 mg/m<sup>2</sup> IV day 1-3</td></tr><tr valign="top"><td rowspan="5"/><td align="center" rowspan="3">3</td><td>BHAC 200 mg/m<sup>2</sup> IV day 1-5</td><td align="center" rowspan="3">1</td><td align="center" rowspan="3">100</td><td align="center" rowspan="3">4</td><td align="center" rowspan="3">3</td><td align="center" rowspan="3">3</td><td align="center" rowspan="3">3</td><td align="center" rowspan="3">3</td><td align="center" rowspan="3">1</td><td align="center" rowspan="3">40.8</td><td rowspan="3"/></tr><tr valign="top"><td>DNR 25 mg/m<sup>2</sup> IV day 1-2</td></tr><tr valign="top"><td>ETP 100 mg/m<sup>2</sup> IV day 1-3</td></tr><tr valign="top"><td align="center" rowspan="2">4</td><td>BHAC 200 mg/m<sup>2</sup> IV day 1-5</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">100</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">40.5</td><td rowspan="2"/></tr><tr valign="top"><td>ACR 10 mg/m<sup>2</sup> IV day 1-5</td></tr><tr valign="top"><td rowspan="5">1st relapse to 2nd CR</td><td rowspan="2">Induction</td><td align="center" rowspan="2">5</td><td>BHAC 200 mg/m<sup>2</sup> IV day 1-8</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">55</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">39.0</td><td rowspan="2">Osteoporotic lumbar compression fracture Pulmonary Aspergillosis</td></tr><tr valign="top"><td>DNR 40mg/m<sup>2</sup> IV day 1-3</td></tr><tr valign="top"><td rowspan="2">Consolidation</td><td align="center" rowspan="2">6</td><td>BHAC 200 mg/m<sup>2</sup> IV day 1-6</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">100</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">38.5</td><td rowspan="2"/></tr><tr valign="top"><td>DNR 40 mg/m<sup>2</sup> IV day 1-3</td></tr><tr valign="top"><td valign="middle"/><td align="center">7</td><td>Ara-C 1 g/m<sup>2</sup> IV x2 day 1-5</td><td align="center">1</td><td align="center">100</td><td align="center">4</td><td align="center">3</td><td align="center">4</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">36.9</td><td/></tr><tr valign="top"><td rowspan="6">2nd relapse to 3rd CR</td><td>Induction</td><td align="center">8</td><td>LDAC day 1-14 with M-CSF day 15-28</td><td align="center">3</td><td align="center">100</td><td align="center">4</td><td align="center">3</td><td align="center">3</td><td align="center">4</td><td align="center">3</td><td align="center">3</td><td align="center">36.5</td><td/></tr><tr valign="top"><td/><td align="center">9</td><td>LDAC day 1-14 with M-CSF day 1-14</td><td align="center">2</td><td align="center">100</td><td align="center">4</td><td align="center">None</td><td align="center">3</td><td align="center">4</td><td align="center">3</td><td align="center">3</td><td align="center">34.9</td><td/></tr><tr valign="top"><td valign="middle">Consolidation</td><td align="center">10</td><td>Same as # 9</td><td align="center">1</td><td align="center">100</td><td align="center">3</td><td align="center">None</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">35.2</td><td/></tr><tr valign="top"><td valign="middle"/><td align="center">11</td><td>Same as # 9</td><td align="center">1</td><td align="center">100</td><td align="center">3</td><td align="center">None</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">36.4</td><td/></tr><tr valign="top"><td valign="middle"/><td align="center">12</td><td>Same as # 9</td><td align="center">1</td><td align="center">100</td><td align="center">3</td><td align="center">None</td><td align="center">4</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">36.4</td><td/></tr><tr valign="top"><td valign="middle"/><td align="center">13</td><td>Same as # 9 </td><td align="center">1</td><td align="center">100</td><td align="center">2</td><td align="center">None</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">2</td><td align="center">37.5</td><td/></tr><tr valign="top"><td rowspan="9">3rd relapse to 4th CR</td><td rowspan="4">Induction</td><td align="center" rowspan="2">14</td><td>LDAC day 1-14 with M-CSF day 1-14</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">100</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">37.5</td><td rowspan="2"/></tr><tr valign="top"><td>VPA 600 mg/day PO</td></tr><tr valign="top"><td align="center" rowspan="2">15</td><td>LDAC day 1-12 with M-CSF day 1-14</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">100</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">None</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2"/><td align="center" rowspan="2"/><td rowspan="2"/></tr><tr valign="top"><td>VPA 600 mg/day PO</td></tr><tr valign="top"><td rowspan="5">Consolidation</td><td align="center">16</td><td>Same as # 15</td><td align="center">1</td><td align="center">100</td><td align="center">3</td><td align="center">None</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">1</td><td align="center">41.3</td><td/></tr><tr valign="top"><td align="center" rowspan="2">17</td><td>LDAC day 1-10 with M-CSF day 1-14</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">100</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2">39.1</td><td rowspan="2"/></tr><tr valign="top"><td>VPA 600 mg/day PO</td></tr><tr valign="top"><td align="center">18</td><td>Same as # 17</td><td align="center">1</td><td align="center">100</td><td align="center">3</td><td align="center">3</td><td align="center">2</td><td align="center">3</td><td align="center">3</td><td align="center">2</td><td align="center">39.4</td><td/></tr><tr valign="top"><td align="center">19</td><td>Same as # 17</td><td align="center">1</td><td align="center">100</td><td align="center">3</td><td align="center">None</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">1</td><td align="center">40.6</td><td/></tr><tr valign="top"><td rowspan="13">4th relapse to 5th CR</td><td rowspan="9">Induction</td><td align="center">20</td><td>LDAC day 1-10 with M-CSF day 1-14</td><td align="center">3</td><td align="center">95</td><td align="center">4</td><td align="center">3</td><td align="center">4</td><td align="center">4</td><td align="center">3</td><td align="center">1</td><td align="center">42.4</td><td/></tr><tr valign="top"><td align="center" rowspan="2">21</td><td>SPAC 200 mg/day PO day 1-14</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">95</td><td align="center" rowspan="2">None</td><td align="center" rowspan="2">None</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">None</td><td align="center" rowspan="2">2</td><td align="center" rowspan="2"/><td align="center" rowspan="2"/><td rowspan="2"/></tr><tr valign="top"><td>G-CSF 100 &#x3BC;g SC day 1-14</td></tr><tr valign="top"><td align="center">22</td><td>Same as # 21</td><td align="center">1</td><td align="center">95</td><td align="center">3</td><td align="center">None</td><td align="center">2</td><td align="center">2</td><td align="center">1</td><td align="center">1</td><td align="center">41.2</td><td/></tr><tr valign="top"><td align="center">23</td><td>LDAC day 1-10 with M-CSF day 1-14</td><td align="center">2</td><td align="center">100</td><td align="center">4</td><td align="center">3</td><td align="center">4</td><td align="center">4</td><td align="center">3</td><td align="center">1</td><td align="center">42.0</td><td/></tr><tr valign="top"><td align="center">24</td><td>LDAC day 1-12 with M-CSF day 1-14</td><td align="center">3</td><td align="center">100</td><td align="center">4</td><td align="center">3</td><td align="center">4</td><td align="center">4</td><td align="center">3</td><td align="center">1</td><td align="center">41.6</td><td/></tr><tr valign="top"><td align="center" rowspan="2">25</td><td>LDAC day 1-12 with G-CSF day 1-12</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">100</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">42.2</td><td rowspan="2"/></tr><tr valign="top"><td>ACR 14 mg/m<sup>2</sup> IV day 1-4</td></tr><tr valign="top"><td align="center">26</td><td>Same as # 25</td><td align="center">2</td><td align="center">100</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">1</td><td align="center">41.7</td><td/></tr><tr valign="top"><td rowspan="4">Consolidation</td><td align="center">27</td><td>Same as # 25</td><td align="center">1</td><td align="center">100</td><td align="center">3</td><td align="center">None</td><td align="center">3</td><td align="center">3</td><td align="center">2</td><td align="center"/><td align="center"/><td/></tr><tr valign="top"><td align="center">28</td><td>Same as # 25</td><td align="center">1</td><td align="center">100</td><td align="center">4</td><td align="center">None</td><td align="center">3</td><td align="center">3</td><td align="center">2</td><td align="center">2</td><td align="center">39.6</td><td/></tr><tr valign="top"><td align="center">29</td><td>Same as # 25</td><td align="center">1</td><td align="center">100</td><td align="center">4</td><td align="center">None</td><td align="center">3</td><td align="center">4</td><td align="center">2</td><td align="center">2</td><td align="center">39.5</td><td/></tr><tr valign="top"><td align="center">30</td><td>Same as # 25</td><td align="center">1</td><td align="center">100</td><td align="center">4</td><td align="center">None</td><td align="center">3</td><td align="center">4</td><td align="center">2</td><td align="center"/><td align="center"/><td/></tr><tr valign="top"><td rowspan="10">5th relapse to 6th CR</td><td rowspan="5">Induction</td><td align="center" rowspan="2">31</td><td>LDAC day 1-12 with G-CSF day 1-12</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">5</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">1</td><td align="center" rowspan="2">40.8</td><td rowspan="2">Depression</td></tr><tr valign="top"><td>ACR 14 mg/m<sup>2</sup> IV day 1-4</td></tr><tr valign="top"><td align="center" rowspan="3">32</td><td>MTX 15 mg + Ara-C 40mg + PSL 10mg IT day -1</td><td align="center" rowspan="3">4</td><td align="center" rowspan="3">5</td><td align="center" rowspan="3">4</td><td align="center" rowspan="3">3</td><td align="center" rowspan="3">4</td><td align="center" rowspan="3">4</td><td align="center" rowspan="3">4</td><td align="center" rowspan="3"/><td align="center" rowspan="3"/><td rowspan="3">Traumatic lumbar compression fracture</td></tr><tr valign="top"><td>LDAC day 1-10 with G-CSF day 1-12</td></tr><tr valign="top"><td>ACR 14 mg/m<sup>2</sup> IV day 1-4</td></tr><tr valign="top"><td rowspan="4">Consolidation</td><td align="center" rowspan="2">33</td><td>LDAC day 1-10 with G-CSF day 1-12</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">5</td><td align="center" rowspan="2">4</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2">3</td><td align="center" rowspan="2"/><td align="center" rowspan="2"/><td rowspan="2"/></tr><tr valign="top"><td>ACR 14 mg/m<sup>2</sup> IV day 1-4</td></tr><tr valign="top"><td align="center">34</td><td>Same as # 33</td><td align="center">1</td><td align="center">75</td><td align="center">4</td><td align="center">None</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">None</td><td align="center">44.0</td><td/></tr><tr valign="top"><td align="center">35</td><td>Same as # 33</td><td align="center">1</td><td align="center">90</td><td align="center">4</td><td align="center">None</td><td align="center">3</td><td align="center">4</td><td align="center">3</td><td align="center">None</td><td align="center">44.6</td><td/></tr><tr valign="top"><td>Maintenance</td><td align="center">36</td><td>SPAC 300 mg/day PO day 1-7 every 4-6 weeks</td><td align="center">1</td><td align="center">100</td><td align="center">None</td><td align="center">None</td><td align="center">None</td><td align="center">None</td><td align="center">2</td><td align="center">2</td><td align="center">36.0</td><td>Sarcopenia</td></tr></tbody></table><table-wrap-foot><p>ACR: aclarubicin hydrochloride, Ara-C: cytarabine, BHAC; behenoyl cytarabine, BI: Barthel index, BW: body weight, DNR: daunorubicin hydrochloride, ETP: etoposide, FN: febrile neutropenia, G-CSF: lenograstim 100&#xA0;&#x3BC;g subcutaneously injected or lenograstim 250&#xA0;&#x3BC;g intravenously injected, IT: intrathecal injection, IV: intravenous injection, LDAC: cytarabine 10&#xA0;mg/m<sup>2</sup> subcutaneously injected twice a day, M-CSF: mirimostim 8 million units intravenously injected, MIT: mitoxantrone hydrochloride, PO: per oral, PS: performance status, SC: subctaneous injection.</p><p>*Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 produced by the National Cancer Institute (<ext-link ext-link-type="uri" xlink:href="http://evs.nci.nih.gov/ftp1/CTCAE/About.html">http://evs.nci.nih.gov/ftp1/CTCAE/About.html</ext-link>).</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Clinical course of the patient.</bold> FISH: fluorescence in situ hybridization, (+): positive, (&#x2212;): negative. *The karyotype was obtained from peripheral blood cells at that time because the patient rejected a bone marrow aspiration procedure.</p></caption><graphic xlink:href="13045_2014_100_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>Our patient received lower doses of cytarabine and daunorubicin than the doses that are considered as standard doses for remission induction of AML with inv(16)(p13.1q22) nowadays, and the suboptimal doses of induction chemotherapy may be the cause of her early relapse. However, higher doses of cytarabine and daunorubicin may have put the 72-year-old woman&#x2019;s life in danger due to associated toxicities. The frail woman eventually went into deep remission after maintenance therapy with a cytarabine prodrug SPAC.</p>
      <p>SPAC has been shown to be as effective and tolerable as LDAC in treatment of AML [<xref ref-type="bibr" rid="CR13">13</xref>-<xref ref-type="bibr" rid="CR15">15</xref>], though its usefulness of SPAC is not well recognized because it is not available outside Japan. In this case, the AML cells were considered as highly sensitive to cytarabine because of repetitive achievement of CR induced by LDAC. Besides, SPAC was associated with fewer toxicities than LDAC (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). LDAC requires the use of subcutaneous injections twice a day, but elderly patients often have difficulties visiting the hospital frequently. On the other hand, SPAC can be orally administered at home. These advantages enabled our patient to continue the maintenance therapy for two years and contributed to her persistent molecular remission. Thus, SPAC potentially offers a chance of cure for elderly patients with inv(16)(p13.1q22) without life threatening toxicities.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec5">
          <title>Additional files</title>
          <p>
            <media position="anchor" xlink:href="13045_2014_100_MOESM1_ESM.doc" id="MOESM1">
              <label>Additional file 1: Table S1.</label>
              <caption>
                <p>Laboratory data of the patient at diagnosis. ALT: alanine aminotransferase, ALP: alkaline phosphatase, APTT: activated partial thromboplastin time, AST: aspartate aminotransferase, AT-III: antithrombin-III, CRP: C-reactive protein, &#x3B3;-GTP: &#x3B3;-glutamyltranspeptidase, LDH: lactate dehydrogenase, PT-INR: international normalized ratio of the prothrombin time, T-Bil: total bilirubin, T-Cho: total cholesterol.</p>
              </caption>
            </media>
            <media position="anchor" xlink:href="13045_2014_100_MOESM2_ESM.pptx" id="MOESM2">
              <label>Additional file 2: Figure S1.</label>
              <caption>
                <p>Smear and karyogram of bone marrow aspirates. A: May-Giemsa-stained smear (x1,000). The blue arrows indicate myeloblasts and monoblasts. The percentage of eosinophils was elevated up to 16.0% of all nucleated cells. The immunophenotype of the blasts was CD2+, CD13+, CD33+, CD34+ and HLA-DR+ (data is not shown). B: Karyogram determined by G-banding. The red arrow indicates inv(16)(p13.1;q22).</p>
              </caption>
            </media>
          </p>
        </sec>
      </app>
    </app-group>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>AML</term>
            <def>
              <p>Acute myeloid leukemia</p>
            </def>
          </def-item>
          <def-item>
            <term>CR</term>
            <def>
              <p>Complete remission</p>
            </def>
          </def-item>
          <def-item>
            <term>LDAC</term>
            <def>
              <p>Low-dose cytarabine therapy</p>
            </def>
          </def-item>
          <def-item>
            <term>SPAC</term>
            <def>
              <p>Cytarabine ocfosfate hydrate</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>All the authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>MA is the doctor in charge of the present case and reviewed guidelines and studies regarding chemotherapy with low-dose agents in elderly patients with AML and wrote the manuscript. YS assisted in preparing the manuscript. HA and SN are medical advisers of hematology and assisted in preparing the manuscript. All authors have read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delaunay</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vey</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Leblanc</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fenaux</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rigal-Huguet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Witz</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <fpage>462</fpage>
          <lpage>469</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-11-3527</pub-id>
          <pub-id pub-id-type="pmid">12649129</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juliusson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Antunovic</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Derolf</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lehmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>M&#xF6;llg&#xE5;rd</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stockelberg</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>113</volume>
          <fpage>4179</fpage>
          <lpage>4187</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-07-172007</pub-id>
          <pub-id pub-id-type="pmid">19008455</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vey</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Coso</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bardou</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Stoppa</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Braud</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Bouabdallah</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The benefit of induction chemotherapy in patients age&#x2009;&gt;&#x2009;or&#x2009;=&#x2009;75 years</article-title>
          <source>Cancer</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>325</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.20353</pub-id>
          <pub-id pub-id-type="pmid">15241830</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pr&#xE9;bet</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Boissel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Reutenauer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Delaunay</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cahn</surname>
              <given-names>JY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: A collaborative study of the French CBF-AML Intergroup</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>4747</fpage>
          <lpage>4753</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2008.21.0674</pub-id>
          <pub-id pub-id-type="pmid">19720919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandwein</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Geddes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kassis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kew</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Leber</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nevill</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus</article-title>
          <source>Am J Blood Res</source>
          <year>2013</year>
          <volume>3</volume>
          <fpage>141</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="pmid">23675565</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Donnell</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Abboud</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Altman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Appelbaum</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Arber</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Attar</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute Myeloid Leukemia</article-title>
          <source>J Natl Compr Canc Netw</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>984</fpage>
          <lpage>1021</lpage>
          <pub-id pub-id-type="pmid">22878824</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D&#xF6;hner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Estey</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Amadori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Appelbaum</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>B&#xFC;chner</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Burnett</surname>
              <given-names>AK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</article-title>
          <source>Blood</source>
          <year>2010</year>
          <volume>115</volume>
          <fpage>453</fpage>
          <lpage>474</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2009-07-235358</pub-id>
          <pub-id pub-id-type="pmid">19880497</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milligan</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Grimwade</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cullis</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Bond</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Swirsky</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Craddock</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guidelines on the management of acute myeloid leukemia in adults</article-title>
          <source>Br J Haematol</source>
          <year>2006</year>
          <volume>135</volume>
          <fpage>450</fpage>
          <lpage>474</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2006.06314.x</pub-id>
          <pub-id pub-id-type="pmid">17054678</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burnett</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Milligan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Prentice</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Goldstone</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>McMullin</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Hills</surname>
              <given-names>RK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment</article-title>
          <source>Cancer</source>
          <year>2007</year>
          <volume>109</volume>
          <fpage>1114&#x2013;</fpage>
          <lpage>1124</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.22496</pub-id>
          <pub-id pub-id-type="pmid">17315155</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferrara</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Palmieri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mele</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia</article-title>
          <source>Haematologica</source>
          <year>2004</year>
          <volume>89</volume>
          <fpage>998</fpage>
          <lpage>1008</lpage>
          <pub-id pub-id-type="pmid">15339685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcucci</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mr&#xF3;zek</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ruppert</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Maharry</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kolitz</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>JO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>5705</fpage>
          <lpage>5717</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2005.15.610</pub-id>
          <pub-id pub-id-type="pmid">16110030</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wakita</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ohtake</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamasaki</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Komatsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Miyazaki</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study</article-title>
          <source>Int J Hematol</source>
          <year>2012</year>
          <volume>96</volume>
          <fpage>84</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1007/s12185-012-1105-y</pub-id>
          <pub-id pub-id-type="pmid">22639053</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kamiya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Urasaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wataya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kawai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsutani</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5&#x2032;-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine</article-title>
          <source>Cancer Res</source>
          <year>1994</year>
          <volume>54</volume>
          <fpage>109</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="pmid">8261429</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okumura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takamatsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Katoh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Murashima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor</article-title>
          <source>Int J Hematol</source>
          <year>1997</year>
          <volume>65</volume>
          <fpage>263</fpage>
          <lpage>268</lpage>
          <pub-id pub-id-type="doi">10.1016/S0925-5710(96)00572-5</pub-id>
          <pub-id pub-id-type="pmid">9114597</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horikoshi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Takei</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hosokawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sawada</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients</article-title>
          <source>Int J Hematol</source>
          <year>2008</year>
          <volume>87</volume>
          <fpage>118</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1007/s12185-007-0019-6</pub-id>
          <pub-id pub-id-type="pmid">18228114</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
